Lipidic Prodrug Co‐Crystals: A Platform for Combination Therapy Targeting Fungal Biofilms
Advanced Materials · 2025
DOI: 10.1002/adma.202510382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025. Verfasst von Yong Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Biofilms, Prodrugs, Antifungal Agents, Lipids. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation Outstanding Youth Project, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Fungal infections are often complicated by biofilm formation and concurrent inflammation, limiting the efficacy of conventional antifungal therapies. To address these challenges, we developed a novel hybrid drug delivery platform—lipidic prodrug co‐crystals (LPCCs)—that combines the benefits of lipidic self‐assembly and pharmaceutical co‐crystallization. In this study, a lipidic prodrug is synthesized by linking catechol‐containing α‐aminophosphonate with phenylboronic acid‐modified bifonazole (Bfz), an antifungal agent, via boronate bonding. The resulting self‐assembled structures exhibit high drug‐loading capacity (up to 85%) and are capable of co‐crystallizing with anti‐inflammatory agents such as nonsteroidal antiinflammatory drugs (NSAIDs) through strong aromatic and ionic interactions. This dual‐delivery system enables the controlled, site‐specific release of both antifungal and anti‐inflammatory agents in response to the acidic and oxidative microenvironment of fungal biofilms. LPCCs effectively prevent biofilm formation, eradicate mature biofilms, and enhance ROS‐scavenging capacity. Mechanistically, LPCCs inhibit the NF‐κB/COX‐2 pathway, reduce pro‐inflammatory cytokines, and promote an anti‐inflammatory M 2 macrophage phenotype. In a murine rectal candidiasis model, LPCCs significantly reduced fungal load, restored tissue integrity, and normalized immune and microbial environments. Our findings highlight LPCCs as a promising strategy for enhancing treatment efficacy, improving patient compliance, and overcoming the limitations of current antifungal therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China.
- Translational Medicine Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
- Wenzhou Institute, University of the Chinese Academy of Sciences, Wenzhou, Zhejiang, 325001, China.
- Guangxi Technology Innovation Cooperation Base of Prevention and Control Pathogenic Microbes with Drug Resistance, Youjiang Medical University for Nationalities, Baise, 533000, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Wenzhou, Zhejiang, 325000,…
- Department of Laboratory Medicine, Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical Uni…
ORCID-Profile: Yong Liu
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation Outstanding Youth Project
- Zhejiang Provincial Natural Science Foundation of China
- TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM reform
- Medical and Health Science and Technology Program of Zhejiang Province
Zitieren
APA
Liu, Y., Gao, C., Zhang, X., Li, W., Huang, Y., Zhou, T., Shao, F., Shi, L., & Li, Y. (2025). Lipidic Prodrug Co‐Crystals: A Platform for Combination Therapy Targeting Fungal Biofilms. Advanced Materials. https://doi.org/10.1002/adma.202510382
Vancouver
Liu Y, Gao C, Zhang X, Li W, Huang Y, Zhou T, et al. Lipidic Prodrug Co‐Crystals: A Platform for Combination Therapy Targeting Fungal Biofilms. Advanced Materials. 2025. doi:10.1002/adma.202510382
BibTeX
@article{Liu2025,
author = {Liu, Yong and Gao, Chang and Zhang, Xiao and Li, Wenlu and Huang, Yanqiang and Zhou, Tieli and Shao, Fanggui and Shi, Linqi and Li, Yuanfeng},
title = {Lipidic Prodrug Co‐Crystals: A Platform for Combination Therapy Targeting Fungal Biofilms},
journal = {Advanced Materials},
year = {2025},
doi = {10.1002/adma.202510382}
}
EUVIMED